|
Hemodynamic Effect of Nasal High-flow in Patients Suspected or Followed for a Precapillary Pulmonary Hypertension
RECRUITINGN/ASponsored by ADIR Association
Actively Recruiting
PhaseN/A
SponsorADIR Association
Started2024-02-13
Est. completion2026-02-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06079151
Summary
In this study, the investigators aim to describe the hemodynamic consequences of nasal high-flow measured during right heart catheterization and echocardiography. The research hypothesis is that nasal high-flow would increase cardiac output in patients with pulmonary hypertension. The concomitant echocardiography will allow to describe its sensibility to detect cardiovascular consequences of nasal high-flow.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: \- patient addressed for right heart catheterization for pulmonary hypertension suspicion or follow-up. Exclusion Criteria: * necessity of FiO2 \>21% during right heart catheterization * intracardiac shunt * grade 4 tricuspid insufficiency * complete arrhythmia due to atrial fibrillation * Pregnant or breastfeeding women or women of childbearing age without an effective method of contraception * protected adult patient (tutorship or curatorship) * patient deprived of liberty by court or administrative decision * refusal of patient participation or consent * patient for whom the measurement of pulmonary arterial pressures during right heart catheterization is impossible * patient for whom, during the etiological assessment of pulmonary hypertension, the diagnosis of precapillary pulmonary hypertension cannot be confirmed and classified in groups 1, 3 or 4.
Conditions2
Heart DiseasePulmonary Hypertension
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorADIR Association
Started2024-02-13
Est. completion2026-02-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06079151